Targets › SLC1A3
1 program from 1 company in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Neurology, Immunology, Ophthalmology; next expected readout Dec 2026.
Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. (UniProt, P43003)
Open in Phaseline: the race on SLC1A3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, Los Angeles | CBD 20 mg GABA-A receptor; anion channel positive allosteric modulator | HTR1A, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, SLC1A2, SLC1A3 | Phase 3 | Spinocerebellar Ataxias; Non-healing Wound; Sleep Apnea, Obstructive; Cervical Spinal Cord Injury … | Dec 2026 |
Spinocerebellar Ataxias (1) Non-healing Wound (1) Sleep Apnea, Obstructive (1) Cervical Spinal Cord Injury (1) Limbal Stem-cell Deficiency (1) Abuse, Drug (1)
small molecule (1)
University of California, Los Angeles (1)
HTR1A (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1) SLC1A2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.